207 filings
ARS
2023 FY
MRSN
Mersana Therapeutics Inc
26 Apr 24
Annual report to shareholders
6:25am
DEFA14A
MRSN
Mersana Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
6:04am
DEF 14A
MRSN
Mersana Therapeutics Inc
Definitive proxy
26 Apr 24
6:02am
8-K
MRSN
Mersana Therapeutics Inc
28 Feb 24
Entry into a Material Definitive Agreement
4:08pm
424B5
MRSN
Mersana Therapeutics Inc
28 Feb 24
Prospectus supplement for primary offering
4:07pm
POS AM
9wwobdct kwt3heghsx
28 Feb 24
Prospectus update (post-effective amendment)
4:05pm
POSASR
naqnzqh0cxvdmzn1 jg
28 Feb 24
Automatic shelf registration (post-effective amendment)
8:43am
8-K
te8029geey5 xvsxmx3
28 Feb 24
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7:07am
S-8
0lg9b9c mh4kq2
12 Jan 24
Registration of securities for employees
4:42pm
8-K
0pf1txmt 8v9s175lp
5 Jan 24
Regulation FD Disclosure
8:06am
8-K
m08v hi1e0ufxk7q8i5e
21 Dec 23
Termination of a Material Definitive Agreement
4:11pm
8-K
og81yhwpg50xv dj32
7 Nov 23
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
7:18am
8-K
mihttltnle thr8w4
31 Oct 23
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
8:12am
8-K
44iumq2zc60zefqvvm7
12 Sep 23
Regulation FD Disclosure
8:27am
8-K
2mi1aum9l
6 Sep 23
Departure of Directors or Certain Officers
7:08am
8-K
9hfwva0n
8 Aug 23
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
8:04am
8-K
fz9mgj0l9 kv
27 Jul 23
Results of Operations and Financial Condition
7:32am